Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.08.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Mordechai Pollak und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Adelson School of Medicine, Ariel University, Ariel, Israel; Pediatric Pulmonology Institute, Schneider's Children's Hospital, Petah Tikvah, Isra…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas Infections, Aminophenols, Benzodioxoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Cystic Fibrosis Society.
Abstract (Originalsprache)
BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) therapy reduces airway infection rates with Pseudomonas aeruginosa (PsA). This study assessed factors associated with sustained chronic PsA infection and evaluated clinical outcomes after one year of ETI, stratified by PsA status. METHODS: Using the European Cystic Fibrosis Society Patient Registry (ECFSPR), we identified people with cystic fibrosis (pwCF) who initiated ETI between 2019 and 2022. Multivariable logistic regression was used to identify clinical and demographic predictors of persistent chronic PsA. Changes in clinical outcomes from one year before to one year after ETI were analyzed using semiparametric models. RESULTS: Among 8188 pwCF with chronic PsA prior to ETI, 4908 (59.9 %) remained chronically infected after one year, while 3280 (40.1 %) transitioned to non-chronic PsA. Older age (OR 1.63, 95 %CI: 1.49-1.78) and lower baseline ppFEV₁ (OR 0.64, 95 %CI: 0.58-0.70) were the strongest predictors of persistent chronic PsA. The improvement in ppFEV₁ was similar between those who remained chronic (12.5 %, 95 %CI: 11.8-13.3) and those who shifted to non-chronic status (13.0 %, 95 %CI: 12.2-13.8; p = 0.074). BMI z-score improvements did not differ significantly between groups (p = 0.086). However, the mean hospital admission days was lower in those who shifted to non-chronic PsA (1.2 vs. 1.9 days; p < 0.001). CONCLUSION: Risk factors for sustained PsA infection post-ETI are associated with older age and lower ppFEV1. Nonetheless, improvements in lung function and nutritional status were comparable, regardless of PsA status. Further research is required to better understand how PsA affects CF lung disease in the era of ETI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Adelson School of Medicine, Ariel University, Ariel, Israel; Pediatric Pulmonology Institute, Schneider's Children's Hospital, Petah Tikvah, Israel. Electronic address: morduchp@gmail.com.
- Laboratory of Medical Statistics, Biometry and Epidemiology "G. A. Maccacaro", Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy.
- Pediatric Pulmonology Institute, Schneider's Children's Hospital, Petah Tikvah, Israel; School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Pulmonology Institute, Hadasah Medical Center, Jerusalem, Israel; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Förderung
- European Cystic Fibrosis Society
Zitieren
APA
Pollak, M., Gambazza, S., Orenti, A., Prais, D., Kerem, E., Mei-Zahav, M., & ECFSPR Steering Group (2025). Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.08.019
Vancouver
Pollak M, Gambazza S, Orenti A, Prais D, Kerem E, Mei-Zahav M, et al. Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.08.019
BibTeX
@article{Pollak2025,
author = {Pollak, Mordechai and Gambazza, Simone and Orenti, Annalisa and Prais, Dario and Kerem, Eitan and Mei-Zahav, Meir and ECFSPR Steering Group, ECFSPR Steering Group},
title = {Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.08.019}
}
EUVIMED